Disclosures

International Anal Neoplasia Society (IANS)
IANS 2025 Scientific Meeting
June 6-8, 2025
RELEVANT FINANCIAL RELATIONSHIPS:

FACULTY/PLANNING COMMITTEE MEMBERS/REVIEWERS/STAFF
ALL RELEVANT FINANCIAL RELATIONSHIPS HAVE BEEN MITIGATED
The following activity planning members reported financial relationships:

Michelle Khan, MD - Research Funds: MagIC Lifescience

Urska Kogovsek, MD - Consultant/Speaker: MSD; Speaker: Takeda

Joseph Terlizzi, MD - Research Funding: SMI Cold Therapy, Merck and Co.,

and Franz Therapeutics

The following activity planning members reported no financial relationships:

Tamzin Cuming, MD Luis Barroso, MD

Jules Bowring, MD Nelson Cavallari, MD

Esther Kuyvenhoven, MD Becca Nowak, MD

David Finch, MD Troy Grennan, MD

Brenton Wait, MD David James, MD

The following activity faculty members reported financial relationship(s):

Andreia Albuquerque, MD - Consultant fee: IQVIA

Alison May Berner, MD - Pfizer, Gilead, Astellas, Lilly, AstraZeneca, Ipsen.

Gary Bucher, MD - Anal Dysplasia Consulting International- President, National Cancer

Institute (NCI); Grant Funding: AIDS Malignancy Consortium (AMC)-PI, Frantz Viral

Therapeutics: Grant Funding; THD America: Consultant

Teresa Darragh, MD – Research Support: Roche

Michael Gaisa, MD – Merck

Luciana La Rosa, MD – Consultant: MSD

Jenny McCloskey, MD - Director HPV Pacific, HPV A, HPVB, WA Medical Laser Centre

Pty Ltd

Joel Palefsky, MD - Merck - Consultant/Honorarium Recipient Vir Biotechnologies;

Consultant/Honorarium Recipient Virion Therapeutics; Consultant/Stock Shareholder

Roche Diagnostics; Abbott - Consultant/Honorarium; Recipient GSK-

Consultant/Honorarium Recipient

Marta del Pino Saladrigues, MD – MSD

David Sebag-Montefiore, MD - University of Oslo consultancy 2024

Sergio Serrano Villar, MD - Funded research: Gilead & MSD; Honoraria: Gilead, Viiv,

Janssen. Patents: bacterial biomarkers for anal dysplasia

ALL OTHER FACULTY/PLANNING COMMITTEE MEMBERS/REVIEWERS/STAFF HAVE NO
RELEVANT FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES